Clindamycin & Seizure Risk: What the Evidence Shows

Overview

Clindamycin is a lincosamide antibiotic used for anaerobic, streptococcal, and staphylococcal infections. Seizures are a rare adverse effect.

Evidence

• Clinical Trials/Post-Marketing: Seizures reported very rarely (<0.1%).
• Mechanism: Unclear; possibly GABA-A receptor antagonism at high CNS concentrations (similar to other β-lactams like imipenem).
• Risk Factors: Pre-existing epilepsy, CNS structural lesions, renal impairment (accumulation), high IV doses, concurrent pro-convulsant drugs.

Clinical Guidance

• For most patients, clindamycin is safe; seizure risk is not a significant concern.
• In patients with seizure history or CNS vulnerability: use with caution, consider alternatives, ensure dose adjustment for renal dysfunction, monitor.
• If seizure occurs: discontinue clindamycin, evaluate for other causes, treat seizure.

Key Point

Do not avoid clindamycin when indicated due to fear of seizures. The benefit-risk ratio is strongly favorable for the vast majority. Individualize for high-risk patients.